DE-DERMALIQ-THERAPEUTICS
Dermaliq Therapeutics, Inc. (Dermaliq), a private biopharmaceutical company with therapeutic focus on dermatology, today announces the formation of a Scientific and Medical Advisory Board composed of internationally recognized experts in dermatology, Gordon Dow (San Francisco, US,), Xavier Yon (Paris, France), Michael Kuligowski, MD, PhD (Chads Ford, US) and R. Todd Plott, MD (Dallas/Fort Worth, US). The Advisory Board is composed of key clinical investigators and industry veterans in the field who support and guide the development of unique topical medications based on our water-free hyliQ technology platform. Mr. Dow has been named Chairman of the Advisory board.
Frank Loescher, PhD, CEO Dermaliq, said, “we are pleased to welcome four highly respected members to our Scientific and Medical Advisory Board as we now advance three programs into the clinic: DLQ01 (Androgenetic Alopecia), DLQ02 (Psoriasis) and DLQ03 (Bacterial Skin and Soft Tissue Infections). The vast clinical and research expertise in dermatology of this group is invaluable for shaping Dermaliq’s current and future product development strategy. The board and the entire team look forward to working closely with them.”
Gordon Dow, PharmD (Chairman) is former CEO, Founder & CTO of Dow Pharmaceutical Sciences Inc, a dermatology specialty company which developed topical products on a proprietary basis, as well as for pharmaceutical and biotechnology companies. Dow was acquired by Valeant, now Bausch Health, for US$ 400 million in 2008. Dr. Dow is a recognized expert in topical product formulations and a leading innovator for a number of approved and successful dermatology products.
Dr. Dow said, “Dermaliq’s hyliQ platform is a step forward in topical formulations and has the potential of being the first real game-changer in dermal delivery since decades.”
Michael Kuligowski, MD, PhD, MBA, is Vice President, Global Product Development, Dermatology at Thermo Fisher. He is an experienced industry dermatologist with 12 years of clinical practice in dermatology, primarily in an academic setting, with strong scientific and clinical background. His pharmaceutical experience spans 25+ years in companies of various sizes In Europe and in North America. Among other successes, Dr. Kuligowski played a key role in the development and approval of the first topical JAK-inhibitor at Incyte where he served as Executive Medical Director, Inflammation & Autoimmunity.
Dr. Kuligowski stated “Better and more effective topical products are needed to serve the needs of patients and practicing physicians. Innovation in the topical space is needed to develop formulations which can provide safe, enhanced drug delivery, especially for substances which are difficult to solubilize and maintain stability. Dermaliq’s novel drug delivery has the promise to address these needs”.
R. Todd Plott , MD, is a board-certified dermatologist in the Dallas/Fort Worth area and Chief Medical Officer of Epiphany Dermatology with 30 years of experience in clinical dermatology. Before entering private practice, Dr Plott spent 16 years in the pharmaceutical industry developing several dermatology drugs widely prescribed by dermatologists, his most notable invention is Solodyn™.
“Treatment of dermatology diseases remains unsatisfactory for many patients. Dermaliq’s lead developments in psoriasis and skin infections offer an intriguing proposition if confirmed in the upcoming clinical trials” said Dr. Plott.
Xavier Yon , is former CEO of Galderma and a seasoned healthcare executive with an extensive background in dermatology. Previous roles include executive positions with Pfizer, Solvay, Alcon and most notably as Chief Executive Officer of Galderma for 17 years. During his time at Galderma Mr. Yon built the company from its initial spin out from Alcon to be a world leader in ethical dermatology. Mr. Yon holds a number of active board and advisor roles. He holds a degree in Physics, Chemistry and Biology from Sorbonne University, Paris.
“Dermaliq offers the opportunity to establish a highly attractive product portfolio based on its hyliQ platform, with increased patient compliance and greater patient satisfaction due to the unique platform-related cosmetic properties”, said Mr. Yon.
About Dermaliq:
Dermaliq Therapeutics, Inc. is a private company founded in 2021 through a spin off from Novaliq to reimagine topical dermatology. The Company is incorporated in Wilmington (DE), USA under Delaware law.
Dermaliq’s mission is to develop a new generation of superior topical therapeutics and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The unique “hyliQTM ” technology is driving a growing product pipeline in key dermatological indications. The technology offers superior bioavailability, stability and cosmetic acceptability.
Dermaliq secured USD 15 million in a series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005539/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ageneau Group Chooses Generix WMS to Boost Growth21.1.2026 09:00:00 CET | Press release
Generix, a global business software company offering an expansive portfolio of SaaS solutions for supply chain, finance, commerce, and B2B integration, announces that Ageneau Group, a French transportation, logistics, and training company, has chosen Generix WMS and TradeXpress to modernize operational processes at its Angers (Trélazé) site, which has a covered area of 9,000 m² and state-of-the-art technological equipment, including automated guided vehicles (AGVs). “We needed a powerful and scalable tool that was in line with our values of cohesion, respect, and innovation. Generix was able to meet 100% of our specifications and support us with transparency and expertise,” said Arnaud Ageneau, co-director of processes, purchasing, and IT at the Ageneau Group. To support its growth and meet the changing needs of its customers, the Ageneau Group was looking for a solution capable of digitizing its operations, optimizing its flows, and providing advanced logistics to its teams. The group
International Zinc Association Partners With Pharmanova to Save Children in Zambia21.1.2026 09:00:00 CET | Press release
Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA), has announced a new partnership with leading Zambian pharmaceutical manufacturer Pharmanova Zambia Limited to expand access to life‑saving zinc treatments for children across Zambia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121178091/en/ Life-saving zinc-supplementation and oral rehydration salts kits are proactively distributed to Zambian children through the works of the International Zinc Association, Pharmanova, and the Zambian Ministries of Health and Education. The collaboration was formally celebrated during a ceremony in Lusaka with the Zambian Ministry of Health, Pharmanova Zambia Limited, and IZA represented by Environment Health & Sustainability Director Dr. Eric Van Genderen. IZA and Pharmanova have united in an effort to scale up treatment for childhood diarrhea using zinc, an essential micronutrient that stre
LatticeFlow AI Acquires AI Sonar, the Leading AI Discovery Platform, to Enable End-to-End, Secure AI Governance21.1.2026 08:22:00 CET | Press release
The acquisition establishes LatticeFlow AI as the industry’s first evidence-based AI governance solution, securely connecting on-prem AI discovery and evaluation with centralized governance operations LatticeFlow AI, a Swiss deep-tech company leading evidence-based AI governance, today announced during the World Economic Forum (WEF) the acquisition of Dublin-based AI Sonar Ltd, a wholly owned subsidiary of CloudSphere Ltd. AI Sonar’s leading edge AI discovery platform allows enterprises and ISVs to detect shadow AI. AI Sonar’s solution will continue to be offered under its brand name by LatticeFlow AI. With this acquisition, LatticeFlow AI will introduce the industry’s first end-to-end, evidence-based AI governance solution securely connecting on-prem AI discovery and evaluations with centralized SaaS governance operations, and covering GenAI, agentic and traditional AI systems. As part of the acquisition, LatticeFlow AI assumes full ownership of AI Sonar’s platform, intellectual prope
Ramboll and Acutro Form Strategic Alliance to Drive Smarter, More Sustainable Intelligent Buildings21.1.2026 08:13:00 CET | Press release
Ramboll, a global leader in engineering, architecture, and consultancy, has entered into a strategic, collaborative partnership with Acutro, specialists in building performance improvement and predictive, data-led maintenance. The partnership brings together Ramboll’s global engineering expertise and Acutro’s digital building intelligence capabilities, creating synergies that support innovation, learning, and value creation for both organisations and their clients. The collaboration enables Ramboll to explore advanced building intelligence tools that can strengthen its digital design capability, while providing Acutro with the opportunity to apply and evolve its platform across complex, real-world projects. Together, the partners will help clients make more informed decisions about performance, lifecycle value, and operational risk. The multi-year relationship provides Ramboll with access to Acutro’s cloud-native platform, creating opportunities to integrate real-time performance analy
STREAMWIDE Marks Major APAC Milestone with UPCAD Public Safety Deployment in the Philippines21.1.2026 08:00:00 CET | Press release
STREAMWIDE has been selected by UPCAD (Unified Platform for Communication and Dispatch) of the Philippines to power its next generation critical communications platform for first responders integrated with national 911 call centers. Through this collaboration, UPCAD integrates STREAMWIDE’s field proven mission critical technology with the national 911 services, the new solution is designed to ensure uninterrupted, secure, and reliable communication during emergencies, enabling faster response times, improved situational awareness, and enhanced public safety outcomes. By integrating directly with 911 call centers, the platform enables real-time sharing of critical information such as caller location, incident details, and response status with first responders and command teams. Through our API, the platform integrates digital workflow capabilities, allowing information to flow seamlessly into the same system. This enables up-to-date reporting while automatically creating incident workfl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom